Foregut malignancy after discordant fecal immunochemical test: A cohort study at a United States safety-net hospital
World Journal of Gastrointestinal Oncology · 15.11.2026 · 18 (11)
DOI: 10.4251/wjgo.123432 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 15.11.2026. Verfasst von Andrew John Cruz und 13 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Whether fecal immunochemical test-positive (FIT+) patients whose colonoscopy does not identify a bleeding source should undergo esophagogastroduodenoscopy (EGD) is unclear. Prior data report foregut cancer rates below 1% in population screening cohorts, but yield by colonoscopy concordance has not been directly compared, particularly in United States safety-net Hispanic populations. AIM To compare the yield of EGD between FIT+ patients with discordant (non-explanatory) and concordant (explanatory) colonoscopy at a safety-net hospital. METHODS We performed a retrospective cohort study of FIT+ adults aged ≥ 45 years who underwent colonoscopy (2019-2025) and EGD within one year at Los Angeles General Medical Center, a safety-net hospital. Colonoscopy was classified as concordant if it identified a lesion plausibly explaining a FIT+ result, including colorectal neoplasia, vascular lesions, or colitis. Foregut malignancy and other EGD findings were compared between groups. Firth penalized logistic regression (exploratory) adjusted for age, sex, anemia, foregut symptoms, nonsteroidal anti-inflammatory drug/aspirin use, and cirrhosis. RESULTS Of 379 FIT+ patients (172 discordant, 207 concordant), 11 foregut malignancies occurred in the discordant group (6.4% vs 0%; P < 0.001; Firth adjusted odds ratio = 26.14, 95%CI: 2.16-315.82). Premalignant lesions were more common in concordant patients (7.7% vs 2.3%, P = 0.02); other EGD findings did not differ significantly between groups. Foregut symptoms were equally prevalent in both groups (44.2% vs 38.2%, P = 0.25), indicating that symptom-driven referral does not account for the observed difference. Among the 11 malignancy patients, 0 were ever-smokers and All patients underwent EGD for standard clinical indications; the observed association reflects a clinically selected cohort rather than protocolized EGD for all discordant patients. CONCLUSION In a clinically selected safety-net cohort, all foregut malignancies occurred exclusively among discordant FIT+ patients despite similar symptom profiles between groups, suggesting that discordant colonoscopy may help stratify foregut malignancy risk in populations with elevated gastric cancer burden.
Zitieren
APA
Cruz, A. J., Gurram, S., Obias, I., Luo, A., Salmastyan, G., Rajagopalan, A., Bui, S., Sharifi, R., Kumar, N., Hui, C., Grave, E. C., Yang, E., Erondu, A., & Griggs, T. (2026). Foregut malignancy after discordant fecal immunochemical test: A cohort study at a United States safety-net hospital. World Journal of Gastrointestinal Oncology, 18(11). https://doi.org/10.4251/wjgo.123432
Vancouver
Cruz AJ, Gurram S, Obias I, Luo A, Salmastyan G, Rajagopalan A, et al. Foregut malignancy after discordant fecal immunochemical test: A cohort study at a United States safety-net hospital. World Journal of Gastrointestinal Oncology. 2026;18(11). doi:10.4251/wjgo.123432
BibTeX
@article{Cruz2026,
author = {Cruz, Andrew John and Gurram, Sandeep and Obias, Isabel and Luo, Allen and Salmastyan, Gevork and Rajagopalan, Aravind and Bui, Stefanie and Sharifi, Roxanna and Kumar, Nikhilesh and Hui, Chester and Grave, Erick Cruz and Yang, Eric and Erondu, Amarachi and Griggs, Theodor},
title = {Foregut malignancy after discordant fecal immunochemical test: A cohort study at a United States safety-net hospital},
journal = {World Journal of Gastrointestinal Oncology},
year = {2026},
volume = {18},
number = {11},
doi = {10.4251/wjgo.123432}
}
EUVIMED